Syncom Formulations (India) liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
12.47×————
3.18×3.18×4.55×2.58×1.61×
2.58×2.58×3.85×2.38×1.42×
11211289.912763.1
22722721116868.5
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SYNCOMF₹20.41

Syncom Formulations (India) Limited

· Pharma & Health
₹ CrorePeersHESTERBIONGLFINEWINDLASJAGSNPHARMAMRUTANJANINDOCOSAIPARENTMcap ₹1,919 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Altman Z-Score (Other Equity as RE)————12.47
Current Ratio1.612.584.553.183.18
Quick Ratio1.422.383.852.582.58
Cash, Equiv & ST Investments63.1127.189.9111.7111.7
Working Capital68.5168.3210.7226.6226.6
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.